key: cord-0760576-ybn2cg9h authors: Poland, Gregory A.; Ovsyannikova, Inna G.; Crooke, Stephen N.; Kennedy, R. ichard B. title: SARS-CoV-2 Vaccine Development: Current Status date: 2020-07-30 journal: Mayo Clin Proc DOI: 10.1016/j.mayocp.2020.07.021 sha: 5025e251207b329a1181d70a8467446a99d31d05 doc_id: 760576 cord_uid: ybn2cg9h Abstract In the midst of the SARS-CoV-2 pandemic and its attendant morbidity and mortality, safe and efficacious vaccines are needed that induce protective and long-lived immune responses. Over 120 vaccine candidates worldwide are in various preclinical, and phase I-III clinical trials that include inactivated, live attenuated, viral vectored replicating and non-replicating), protein and peptide-based, and nucleic acid approaches. Vaccines will be necessary both for individual protection and for the safe development of population-level herd immunity. Public-private partnership collaborative efforts, such as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) mechanism, are key to rapidly identifying safe and effective vaccie candidates as quickly and efficiently as possible. In this article, we review the major vaccine approaches being taken and issues that must be resolved in the quest for vaccines to prevent COVID-19. We scanned the PubMed database from 1963–2020 for all publications using the following search terms in various combinations: SARS, MERS, COVID-19, SARS-CoV-2, vaccine, clinical trial, coronavirus, pandemic, vaccine development. We also did a web search for these same terms. We also examined the World Health Organization, Centers for Disease Control and Prevention, and other public health authority websites. We excluded abstracts and all articles that were not written in English. SARS-CoV-2 is the second virus to cause a human pandemic in the 21 st century and the third novel betacoronavirus to emerge as a human pathogen in the last 18 years. 1 As of this writing, over 13 million cases have been identified worldwide, and almost 600,000 deaths have been reported. 2 These are certainly underestimates, in part related to the now-apparent wide spectrum of disease ranging from asymptomatic individuals, to severe disease, to death, as well as the dearth of diagnostic testing and standardized reporting. In a mere 28 weeks, we have learned much, but far more remains to be learned. The genetic sequence of SARS-CoV-2 was solved very quickly, and within weeks the sequence was widely available, identifying it as a betacoronavirus with close genetic similarity to SARS-CoV-1. We have learned the cellular receptor used by this virus and the concomitant inflammatory cytokine storm that can result from infection. We have identified the approximate reproductive number and the infection fatality rate of SARS-CoV-2 and are witnessing the wide spectrum of clinical and human immune responses to infection with the virus. We have also learned that severe disease and death vary by patient age, comorbidities, smoking status, BMI, when in the context of a localized epidemic one presents for medical care, and other factors. At this time, there are no validated point-of-care assays for rapid diagnostics that have been widely deployed, no licensed antivirals, and no licensed vaccines for use in civilian populations. Absent a safe and effective vaccine, safe achievement of herd immunity will prove elusive. While multiple vaccine candidates were developed against the SARS-CoV-1 and MERS viruses, no vaccine candidates progressed past phase I studies. This review will focus on the current development of SARS-CoV-2 vaccines and address issues relevant to devising a safe and effective vaccine. To gather material for this review, we scanned the PubMed database from 1963-2020 for all publications using the following search terms in various combinations: SARS, MERS, COVID-19, SARS-CoV-2, vaccine, clinical trial, coronavirus, pandemic, vaccine development. We also did a web search for these same terms. We also examined the World Health Organization, Centers for Disease Control and Prevention, and other public health authority websites. In December 2019, a cluster of atypical viral pneumonia cases in Wuhan, China, was reported to the World Health Organization (WHO). It was reported that most patients exhibited respiratory symptoms consistent with severe acute respiratory disease (SARS) and had previously visited the Huanan seafood wholesale market, suggesting an animal origin of SARS-CoV-2. Subsequently, person-to-person transmission through droplets or direct contact occurred, resulting in the early January 2020 declaration by Chinese health authorities that a novel coronavirus (2019-nCoV) had been identified and isolated from patients in Wuhan. [3] [4] [5] Within a month, the full-length genomic sequence of the new coronavirus was made available to the WHO and became publicly available. 6 SARS-CoV-2 has rapidly spread across the globe. 7 On January 30, 2020, the WHO declared the SARS-CoV-2 epidemic a global health emergency. By March 11, 2020 , the WHO declared a pandemic. The rapid transmission of SARS-CoV-2 has caused fear, panic, economic disruption, morbidity and mortality, and significant public health concerns. 8 Recent data have demonstrated that the clinical characteristics of COVID-19 disease can be very heterogeneous with a broad spectrum of severity, including illness resulting in death. 9 Data demonstrate that asymptomatic individuals can transmit SARS-CoV-2 infection. 10 Individuals over 65 years of age, individuals of all ages who have serious underlying medical conditions, and those who are immunocompromised are at higher risk of serious COVID-19 illness and complications. Although COVID-19 has been detected in equal numbers of confirmed cases between males and females, there appear to be sex-based differences in severity and mortality to the disease (i.e., higher mortality in older male patients). 11, 12 Considering the alarming outcomes of the current COVID-19 pandemic, it is critical to develop safe and effective vaccines and antiviral agents to prevent, control, and treat COVID-19. 13 The SARS-CoV-2 virus shares up to 82% nucleotide identity with human SARS-CoV-1 and utilizes the same host cellular receptor as SARS-CoV-1, called the ACE2 (angiotensinconverting enzyme 2), 14 as an entry receptor into host cells. 15 Data from initial COVID-19 studies revealed that ACE2 is differentially expressed in many human tissues, such as lung (alveolar cells type 2), liver (cholangiocytes), stomach (epithelial cells), ileum (enterocytes), kidney (proximal tubules), and colon (colonocytes). 16 Notably, the cellular serine protease TMPRSS2 (also a host cell factor for influenza A and other coronaviruses) has recently been demonstrated as critical for activation of the SARS-CoV-2 trans-membrane spike (S) glycoprotein (i.e., the main target of neutralizing antibodies), priming, and viral cell entry. 17 Little is known about SARS-CoV-2-specific immune responses during COVID-19 infection. Histopathology, immunohistochemistry, in situ hybridization, and electron microscopy data from SARS-CoV-1-infected human lung tissue revealed that SARS-CoV-1 can infect and replicate in alveolar macrophages, type I and type II pneumocytes, and bronchiolar epithelial cells. 20, 21 Both Th1-type (IFNγ, IL-1β, IP10, MCP1 and IL-6) and Th2-type (IL-4 and IL-10) cytokines are produced in high concentrations in plasma in response to SARS-CoV-2 infection, indicating that the host immune response itself is involved in disease progression and pathogenesis. 22 In silico study results demonstrate that SARS-CoV-2 S protein induces an innate inflammatory immune response via NF-kB activation and possibly thru TLR4 ligand. 23 High concentrations of pro-inflammatory and anti-inflammatory cytokines (e.g., IL-2R, IL-6, IL-10 and TNF-α) have been detected in serum samples from severe cases of COVID-19 disease compared with levels in serum from moderate cases. This suggests that a massive cytokine storm likely contributes to disease severity. 24 Other factors that have been reported to be associated with disease severity outcomes (e.g., lymphopenia, decrease in CD4+ and CD8+ T lymphocyte counts, suppressed IFN-γ secretion by CD4+ T lymphocytes, and lower counts of CD16+CD14+ monocytes) may also be potential significant immunologic markers of severe and moderate COVID-19. 24, 25 As per a recent case study report, the increased frequency of antibody-secreting cells, follicular helper T cells, activated CD38+ HLA-DR+ CD8+ and CD4+ T lymphocytes, together with SARS-CoV-2-specific IgG and IgM antibodies, detected in the blood of a patient with nonsevere COVID-19 prior to symptomatic recovery, suggests that early adaptive immune-related biomarkers may be predictors of better clinical outcomes. 25 Given SARS-CoV-2 pathogenesis and tissue tropism, and the significant morbidity and mortality at the public health level, it is essential to develop an effective vaccine to protect against SARS-CoV-2. nucleotide substitution per base per year). 32 33 The SARS-CoV-2 genome exhibits a mutation rate of <25 mutations per year, which is much slower than seasonal influenza virus, but it is virtually certain that further mutations and recombination events will be identified. The receptor binding domain (RBD) of the S protein is a critical factor for binding to ACE2 and to determine tropism and infectivity of SARS-CoV-2. 14 Previous mutagenesis studies have suggested that the cross-neutralization resistance between SARS-CoV and palm civet-CoV may result in mutations within the RBD of the S protein. 34 Recent structural analysis of S protein-ACE2 receptor complexes identified several amino acid substitutions and deletions in the SARS-CoV-2 RBD of S protein (i.e., S1 subunit) compared to those of SARS-CoV and Bat-CoV. 35 These mutations resulted in a higher affinity of the SARS-CoV-2 S protein to the human ACE2 in comparison with SARS-CoV and Bat-CoV. 35 This is likely associated with the dynamic of viral spreading. Another genetic study examining amino acid mutations in circulating SARS-CoV-2 RBDs has found eight mutation types (from a total of 18 mutant strains) that were divided into two different groups of amino acid mutations in SARS-CoV-2 RBD domain based on human ACE2 affinity to the S protein (i.e., the "similar affinity" group: V341I, F342L, R408I, A435S, V483A; and significantly "higher affinity" group: N354D, D364Y, V367F, W436R). 36 The study investigators proposed that the "higher affinity" group of mutated amino acids (specifically, amino acid mutation V367F) demonstrated an enhancement of SARS-CoV-2 binding affinity to human ACE2 and may have allowed for increasingly significant infectivity and more severe virus transmission. 37 A pipeline data analysis of real-time mutations in SARS-CoV-2 identified 14 mutations in S protein (including mutation D614G) and a viral recombination event. Recent reports have demonstrated that the D614G mutation increases infection of human cell lines, [38] [39] [40] with mounting evidence that it also influences disease severity. 41 A study published by Fehr and Perlman 42 demonstrated that the human SARS-CoV-2 genome is similar to that of other RNA viruses and encodes for four major structural proteins, including the surface spike (S), small envelope (E), membrane (M), and nucleocapsid (N) proteins. The CoV genome also encodes for 5'nonstructural (n=16) and lineage-specific accessory genes (n=6, functionally not well characterized). The Betacoronaviruses HCoV-OC43 and HCoV-HKU1 have also been found to encode for an additional structural hemagglutinin esterase (HE) protein that may enhance the S protein-mediated viral infection and generation of infectious virions. 43 The S protein is implicated in host cell invasion and is cleaved by furin-like enzymes into two functional subunits or regions, S1 and S2, which are responsible for host cell receptor binding and host receptor membrane fusion, respectively. 44, 45 The S protein of SARS-CoV-2 is primed/activated by the cellular serine protease TMPRSS2, which is essential for viral entry and spread in the infected host. 17 The main factor determining SARS-CoV-2 tropism is the RBD of S protein, which binds to the host receptor ACE2 and can only interact with the RBS when it is in the hinge-like "up" conformation in SARS-CoV-2. 46 Notably, SARS-CoV-2 and SARS-CoV share a conserved epitope in the RBD that may be an important consideration in SARS-CoV-2 vaccine antigenicity and cross-protective antibody responses. This remains to be further elucidated. The WHO is coordinating an international group of experts (e.g., scientists, physicians, and industry leaders) who are working to create vaccine candidates and has released a Target Product Profile. 47 that includes both critical and preferred characteristics -the ideal vaccine will have the features outlined in Table 1 . The FDA has recently issued a guidance document on COVID-19 vaccines. 48 This document is primarily focused on regulatory requirements and key considerations for licensure data such as the following: pre-clinical data, characterization of immune responses in animal models, toxicity, minimum efficacy requirements, and the potential for vaccine-associated enhanced respiratory disease. Despite the relatively mild disease seen in most infants and children and given the relative ease of transmission of SARS-CoV-2, vaccines targeting this audience must also be developed. It is likely that multiple vaccine candidates, each geared toward specific population groups at increased risk, will be necessary. Because we have never had a coronavirus vaccine, it is also likely that we will need long-term data on multiple vaccines in order to identify products that Data from studies on SARS and MERS vaccine candidates have shaped much of the early vaccine development efforts to SARS-CoV-2. 50 Preclinical studies, animal models, and other data have been used to accelerate vaccine development for SARS-CoV-2. These data indicate the following: 1) the S protein is the major target of neutralizing antibodies; 51 2) many of these antibodies target the RBD of S protein; 52-54 3) neutralizing antibodies generated by vaccination or adoptively transferred are protective in animal models (e.g., mice, rabbits, and non-human primates); 55, 56 4) clinical trials of two MERS vaccines, a DNA-based vaccine consisting of the S protein and a replication-deficient chimpanzee adenovirus expressing the S protein, both elicit robust antibody responses; 5) an MVA-based vaccine expressing the S protein has been used to vaccinate camels and significantly reduces viral loads and virus secretion; 57 and 6) most of the vaccine candidates also induced cellular immunity, which is thought to be critical to viral clearance. [58] [59] [60] Work in these areas continues with an expanded scope that now includes this latest novel coronavirus. This same body of work with SARS and MERS has demonstrated that there are also obstacles that we must carefully navigate. One serious issue is antibody-dependent enhancement (ADE) of infection and disease that has been noted in SARS. 61 Interestingly, antibodies targeting the S protein were found to mediate ADE, 62 which results in enhanced infection of macrophages and B cells; 63, 64 therefore, S only protein-based vaccines must be carefully evaluated in terms of safety. Another obstacle facing vaccine development is the fact that animal studies of SARS and MERS vaccines (including formulations that moved into phase I clinical trials) found evidence of lung and/or liver pathology after live-virus challenge. [65] [66] [67] [68] Eosinophilic infiltration, enhanced Th2 responses, and increased infectivity have been noted with both whole virus vaccines and with full-length S protein-based vaccines. 69 The ability of a vaccine to elicit a robust, Th1 type T helper response is considered ideal, given the antiviral properties of this type of response and its suppressive effect on Th2 responses. 70 Yet another issue is the observed lack of durable protective immunity to seasonal coronaviruses. It remains to be seen if the appropriate use of adjuvants and highly immunogenic vaccination platforms are able to overcome this problem. A number of studies have begun to examine immune responses to SARS-CoV-2 and have found that antibody responses (IgM, IgG, IgA) appear 1-2 weeks after infection, peak several weeks later, and then decline. Humoral immunity targets the S and nucleocapsid proteins, with neutralizing antibody primarily directed against the receptor binding domain of the S protein. [71] [72] [73] [74] [75] [76] Similarly, infection induces T cell responses (primarily Th1) against a broad range of viral proteins. [77] [78] [79] [80] [81] [82] It has also been shown that T follicular helper responses occur and are correlated with the magnitude of the humoral response. 83 T cell repsonses have also been detected in individuals lacking humoral immunity. 84 Despite these initial findings, our understanding of SARS-CoV-2 immunity is far from complete; therefore, further studies examining innate, humoral, and cellular immune responses to this new virus are necessary in order to fully understand mechanisms of protection that need to be activated by COVID-19 vaccines. As the immune response to SARS-CoV-2 has not yet been fully characterized, we have a very limited understanding of the viral proteins that may be important targets of the immune system, which could beuseful for developing effective vaccine candidates. In this respect, predictive computational algorithms may prove to be beneficial tools for the identification of immunogenic T cell and B cell epitopes that can accelerate the rational design of SARS-CoV-2 vaccine formulations. Computational algorithms offer the distinct advantage of rapidly screening the entire amino acid sequence of viral proteins to predict peptides with high antigenicity or binding affinity for HLA molecules-a task that would take countless hours to accomplish in the laboratory while consuming valuable biological specimens. Advancements in machine learning, artificial neural networks, and other computational fields have led to the continued development and refinement of epitope prediction algorithms with improved accuracy, 85 identified both T cell and B cell epitopes from the MERS-CoV S protein that were conserved across clinical isolates, suggesting these epitopes may be used to develop broadly protective vaccines. 96 A similar study focused on the MERS-CoV N protein as a potential vaccine target, identifying candidate B cell (15 linear, 10 conformational) and T cell (10 T-helper, 10 cytotoxic) epitopes for further study. 97 Once individual peptide epitopes have been identified by immunoinformatic approaches, they can be computationally modeled as larger polypeptide assemblies for immunologic evaluation. Srivastava and colleagues employed such an approach to identify cytotoxic and helper T cell epitopes from the MERS-CoV proteome and design two vaccine constructs, both of which were predicted to provide broad global HLA population coverage (94%) and dock with Toll-like receptors. 98 Applying similar immunoinformatic approaches, we comprehensively analyzed 10 SARS-CoV-2 proteins to identify potential targets for inclusion in COVID-19 vaccines. 99 Similar studies detailing the in silico prediction of T cell and B cell epitopes from SARS-CoV-2 began to rapidly emerge following publication of the viral genome sequence. Grifoni et al. reported the bioinformatic identification of T cell and B cell epitopes from SARS-CoV-2 structural proteins that possessed high homology with immunogenic epitopes from SARS-CoV- based on B cell antigenicity scoring or HLA binding affinity, [101] [102] [103] [104] [105] with several designing polypeptide vaccine candidates and modeling their binding with HLA and TLR molecules. [106] [107] [108] We have pursued a similar approach, stringently applying combinations of in silico approaches to identify subsets of T cell (CD4 + and CD8 + ) and B cell (linear and conformational) epitopes from the SARS-CoV-2 proteome to serve as candidates for peptide-based vaccine development (unpublished results). These studies demonstrate the utility of bioinformatics and computerbased predictive modeling for designing vaccines against rare and emerging diseases when immunological data and biological samples are limited. Some of the first vaccines are already in clinical trials 4-5 months after the start of the outbreak. As of the time of this writing, one vaccine has been licensed in China only for use in Chinese military, three vaccines are in phase III trials, eight are in phase II trials, 11 are in phase I trials, and the remainder in preclinical studies. This amazingly rapid development cycle is due to several factors: existing vaccine candidates, data, and animal models from SARS and MERS; the early publication of the full-length genome sequence of SARS-CoV-2; the striking sequence similarity in the S protein between SARS-CoV-1 and SARS-CoV-2; the use of DNA and RNA "plug and play" vaccine platforms; and reduced regulatory burdens due to the urgent nature of the outbreak (Figure 1 ). Examination of the T cell responses in the two lower vaccine-dose (25ug and 100ug) groups and identified the presence of SARS-CoV-2 specific CD4+ T cells with a Th1 phenotype. Virusspecific CD8 T cells were detected in the 100ug vaccine group. With regard to safety, no serious adverse events were noted; however, fatigue, chills, headache, myalgia, and pain at the injection site were common (i.e., reported in >50% of recipients). Local adverse events were typically mild, although severity was more pronounced at higher doses. Of the five grade-two adverse events noted, only two were deemed to be related to the vaccine. Both (elevated lipase and decreased hemoglobin) occurred seven days after the second vaccination. NIH is now recruiting two additional age groups (51-70 years old and ≥71 years old) to evaluate the vaccine in older populations in a phase II clinical trial and is seeking regulatory approval for a much larger scale Phase III trial to begin during the Summer of 2020. Inovio has developed a DNA-based vaccine that is injected and then electroporated into muscle cells in order to induce host cell production of the S protein. There are over 120 additional vaccines in various stages of preclinical development, and the number increases weekly. [110] [111] [112] This vaccine uses a saponin-based adjuvant, which is a formulation that has been shown to enhance adaptive immune responses to recombinant Ebola glycoprotein vaccines and MVAbased influenza vaccines. 119, 120 CEPI has also partnered with the University of Queensland to develop a protein-based vaccine that uses a "molecular clamp" to lock the coronavirus proteins into the correct three-dimensional shape, allowing humoral immune responses to develop against appropriate conformational epitopes. 121 Vaxart is developing an oral tablet-based vaccine that uses a replication deficient Adenovirus 5 vector to deliver recombinant S protein and a TLR3 adjuvant to the mucosal epithelium. 122 An Israeli company, MigVax, is also developing an oral subunit vaccine against COIVD-19. This product is based on their existing vaccine against poultry coronaviruses 123 Group is working on a peptide-based vaccine using naturally processed and presented epitopes from multiple SARS-CoV-2 proteins identified through mass spectrometry. 95, 124-127 Virus-like particle (VLP) vaccines are a type of subunit vaccine consisting of an empty virus shell that lacks nucleic acid and is therefore non-infectious. VLPs retain the three-dimensional structure and repetitive antigenic nature of viral particles and have been found to be extremely immunogenic. 128 Nearly a dozen groups are working on VLP platforms expressing S protein or RBD. The University of Pittsburgh Medical Center has developed a microneedle skin-patch vaccine for SARS-CoV-2 that induced neutralizing antibody production in mice. 129 Nucleic acid vaccines Nucleic acid vaccines can be rapidly and inexpensively produced and contain no live virus; however, DNA vaccines require complicated delivery systems, generally higher doses, and are more difficult to produce. RNA vaccines may suffer from transfection efficiency issues in vivo. Novel human coronavirus (SARS-CoV-2): A lesson from animal coronaviruses World Health Organization. Coronavirus disease (COVID-19) Situation Report -162 A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Origin and evolution of pathogenic coronaviruses CoV-2: a time for clear and immediate action Clinical Characteristics of Coronavirus Disease 2019 in China A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses Genetic variation in neuraminidase genes of influenza A (H3N2) viruses Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis RBD mutations from circulating SARS-CoV-2 strains enhance the structural stability and human ACE2 affinity of the spike protein Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv. Preprint posted online The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types. bioRxiv. Preprint posted online The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality? Coronaviruses: an overview of their replication and pathogenesis The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV World Health Organization. WHO Target Product Profiles for COVID-19 Vaccines Food and Drug Administration, Center for Biologics Evaluation and Research. Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry A strategic approach to COVID-19 vaccine R&D Antibodies and vaccines against Middle East respiratory syndrome coronavirus Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformationdependent epitopes that induce highly potent neutralizing antibodies Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels Rapid generation of a mouse model for Middle East respiratory syndrome T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirusinfected mice Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Immunization with modified vaccinia virus Ankarabased recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets Immunopathogenesis of coronavirus infections: implications for SARS Rapid COVID-19 vaccine development Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2 Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection. bioRxiv. Preprint posted online Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomised, first-in-human trial SARS-CoV-2-specific T cells exhibit unique features characterized by robust helper function, lack of terminal differentiation, and high proliferative potential Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. bioRxiv Prediction of epitopes using neural network based methods Machine learning-based methods for prediction of linear B-cell epitopes Prediction of MHC class II binding affinity using SMMalign, a novel stabilization matrix alignment method Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions NetMHCpan, a method for MHC class I binding prediction beyond humans NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data Improved methods for predicting peptide binding affinity to MHC class II molecules Improved method for predicting linear B-cell epitopes Prediction of residues in discontinuous B-cell epitopes using protein 3D structures Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV In the search of potential epitopes for Wuhan seafood market pneumonia virus using high order nullomers In silico identification of vaccine targets for 2019-nCoV Human leukocyte antigen susceptibility map for SARS-CoV-2 Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach 3CL Hydrolase Based Multi Epitope Peptide Vaccine Against Sars-CoV-2 Using Immunoinformatics An mRNA Vaccine against SARS-CoV-2 -Preliminary Report The SARS-CoV-2 Vaccine Pipeline: an Overview Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates Live-attenuated H1N1 influenza vaccine candidate displays potent efficacy in mice and ferrets Extensive recoding of dengue virus type 2 specifically reduces replication in primate cells without gain-of-function in Aedes aegypti mosquitoes Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice Matrix-M adjuvant enhances immunogenicity of both protein-and modified vaccinia virus Ankara-based influenza vaccines in mice UQ COVID-19 vaccine shown to induce potent protective response in pre-clinical trials Five COVID-19 Vaccine Candidates in Preclinical Testing Immune responses to mucosal vaccination by the recombinant A1 and N proteins of infectious bronchitis virus Mass spectrometry and peptide-based vaccine development Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood Major findings and recent advances in virus-like particle (VLP)-based vaccines Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development China fast-tracks novel coronavirus vaccine development World Health Organization. DRAFT landscape of COVID-19 candidate vaccines Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. medRxiv Serologic classification of chimpanzee adenoviruses by hemagglutination and hemagglutination inhibition AstraZeneca agrees to make COVID-19 vaccine for Europe Researchers in Pittsburgh, Paris and Vienna Win Grant for COVID-19 Vaccine The authors thank Caroline L. Vitse for her editorial assistance with this manuscript.